Applicants: Gregory B. Wilson et al.

Serial No.: 09/776,010 Filed: February 2, 2001

Page 2

Listing of Claims

- 1-31. (Canceled)
- 32. (Currently Amended) A cell-free fluid consisting essentially of a mammary gland secretion of a human herpesvirus-6A immunized lactating bovid mammal.
- 33. (Currently Amended) A cell-free fluid consisting essentially of a mammary gland secretion of a human herpesvirus-6B immunized lactating bovid mammal.
- 34. (Canceled)
- 35. (Canceled)
- 36. (Previously Presented) The cell-free fluid of claim 32 in the form of a lyophilized product.
- 37. (Previously Presented) The cell-free fluid of claim 33 in the form of a lyophilized product.
- 38. (Previously Presented) A pharmaceutical composition comprising an effective amount of the cell free fluid of claim 32 and a pharmaceutically acceptable carrier.
- 39. (Previously Presented) A pharmaceutical composition comprising an effective amount of the cell free fluid of claim 33 and a pharmaceutically acceptable carrier.
- 40. (Previously Presented) A method of treating chronic fatigue syndrome in a human which comprises orally administering to the human an amount of a cell-free fluid

Applicants: Gregory B. Wilson et al.

Serial No.: 09/776,010 Filed: February 2, 2001

Page 3

consisting essentially of a mammary gland secretion of a human herpesvirus-6A immunized lactating mammal and an amount of a cell-free fluid consisting essentially of a mammary gland secretion of a human herpesvirus-6B immunized lactating mammal effective to treat chronic fatigue syndrome in the human.

- 41. (Canceled)
- 42. (Previously Presented) A method of treating chronic fatigue syndrome in a human which comprises orally administering to the human the pharmaceutical composition of claim 38, so as to thereby treat chronic fatigue syndrome in the human.
- 43. (Previously Presented) A method of treating chronic fatigue syndrome in a human which comprises orally administering to the human the pharmaceutical composition of claim 39, so as to thereby treat chronic fatigue syndrome in the human.
- 44. (Canceled)
- 45. (Canceled)
- 46. (Currently Amended) A pharmaceutical composition comprising an amount of a cell-free fluid consisting essentially of a mammary gland secretion of a human herpesvirus-6A immunized lactating bovid mammal and an amount of a cell-free fluid consisting essentially of a mammary gland secretion of a human herpesvirus-6B immunized lactating bovid mammal effective to treat chronic fatigue syndrome in a human subject and a pharmaceutically acceptable carrier.

Applicants: Gregory B. Wilson et al.

Serial No.: 09/776,010 Filed: February 2, 2001

Page 4

47. (Previously Presented) A method of treating chronic fatigue syndrome in a human which comprises orally administering to the human the pharmaceutical composition of claim 46, so as to thereby treat chronic fatigue syndrome in the human.